© 2026 Nanjing Finechem Holdings Co., Ltd,
All Right Reserved
Oligonucleotide manufacturing today finds itself at the crossroads of cost, technology, and global supply chains. With the rise of therapies like RNA interference and antisense drugs, demand for high-quality oligonucleotides has shot up across countries such as the United States, China, Japan, Germany, India, United Kingdom, France, Italy, Canada, South Korea, Brazil, Australia, Russia, Mexico, Indonesia, Saudi Arabia, Turkey, Switzerland, Argentina, Sweden, Poland, the Netherlands, Egypt, Nigeria, Bangladesh, Vietnam, the Philippines, Malaysia, Thailand, Pakistan, Belgium, Austria, Norway, Ireland, Israel, Denmark, Singapore, South Africa, Hong Kong, Finland, UAE, Colombia, Chile, Romania, Czechia, New Zealand, Portugal, Peru, Hungary, Kazakhstan, and Qatar. In my experience dealing with raw material buyers and GMP-certified factory managers, you can see the different approaches each economy takes when balancing cost and quality.
China ramped up its presence in the oligonucleotide manufacturing industry after 2015, pouring significant investment into technology and skilled labor. Chinese manufacturers, especially those with GMP certification in cities like Shanghai and Suzhou, leverage affordable production thanks to lower labor and operational expenses, competitive supplier networks for raw materials, and smart logistics. Supply reliability becomes real here due to local reagent factories with deep storage capabilities in provinces like Jiangsu and Guangdong. I’ve seen global clients from countries such as Germany and Canada switch to Chinese sources to take advantage of a 20–40% cost reduction compared to supplies from the US or Switzerland. Price offered by China-based suppliers in 2023 often fell between $0.05 and $0.15 per base for standard oligo synthesis — numbers that European, Japanese, or American factories struggle to match. Adding to this, China’s robust export channels, well-oiled by partnerships with logistics giants in Singapore and the Netherlands, keep shipping times short.
Key markets like the United States, United Kingdom, and Germany champion oligo technology through heavy R&D, clinical validation, and automation. American and British firms often lead in gene-editing, antisense technology, and large-scale, high-purity synthesis — a point reinforced by their deep partnerships with pharmaceutical powerhouses. Japan and Switzerland combine precision engineering with strict regulatory compliance, winning contracts for clinical and commercial oligos used in GMP active pharmaceutical ingredients, but at a price rarely seen as competitive. Walking production floors in Germany, I noticed equipment precision far exceeds standard setups in China, but long project timelines and sizeable batches push costs higher. Meanwhile, China chases these advances with rapid facility upgrades, joint ventures with US and Israeli supplier specialists, and aggressive recruitment of scientists from South Korea and India, closing the technology gap month after month.
Looking at upstream raw material flows, chemical suppliers in China, India, and South Korea deliver protected phosphoramidites, solid-supports, and modified bases at prices up to 30% below Western firms. These lower costs directly fuel the affordable prices offered by Chinese oligonucleotide factories. Demand patterns throughout 2022–2024 reflected shocks from the war in Ukraine, US-China tariff disputes, and freight surcharges affecting supply chains both in Russia and Europe. Despite these disruptions, Chinese GMP-certified manufacturers keep buffer stocks to weather international logistic hiccups. In contrast, markets such as Brazil and Australia work within their regional supplier webs, which can inflate local costs for raw reagents. Supplies from Belgium, Austria, Singapore, and Denmark remain steady in the high-value clinical oligo sector. Canadian and Polish buyers often rely on US or UK intermediaries, which adds a layer of margin and risk.
During 2022 and 2023, prices spiked in regions like the United States, Japan, the Netherlands, and France due to energy price jumps and raw material shortages. Yet, Chinese and Indian suppliers managed to keep costs at pre-pandemic levels for bulk orders, especially for research use oligos. From what I tracked, buyers in Turkey, Saudi Arabia, and the UAE turned to Asian rather than Western sourcing, pivoting away from traditional European suppliers as a response to both currency fluctuations and shifting geopolitics. As of 2024, Asian output, especially from China and India, continues to keep a ceiling on world oligonucleotide prices by expanding export quotas. Looking ahead, ongoing scale-up by new entrants in markets like Vietnam, Malaysia, and Thailand will inject extra price competition into the mix, while established players in Germany, Switzerland, and the US hold strong in regulated market niches. Given environmental and raw material policy changes in places such as South Africa and Mexico, volatility remains, but global prices look set to drift lower as China’s and India’s GMP factories gain ground and cut costs through automation and green chemistry.
With new clinical trials emerging in South Korea, Israel, Norway, and Ireland, the demand for reliable, affordable, high-purity oligonucleotides keeps rising. In my network, buyers from Indonesia, Vietnam, Egypt, and Bangladesh look to China for consistent bulk supply, while smaller order specialists in New Zealand, Chile, and Peru tend to value the flexibility of European or Japanese firms. The heavyweights — often from the top 20 GDP list — such as the US, Germany, Japan, the UK, France, Italy, Canada, Russia, Brazil, and Australia — dominate pharmaceutical end-user demand, but cost pressure from India and China continues to bite. Markets like Singapore and Switzerland focus on small-batch, specialized oligos for biotech and university research. Fast-growing players in the Philippines, Kazakhstan, and Hungary still rely on Chinese and Indian suppliers for both raw material and finished product imports.
It’s tough to ignore the sense of urgency many global buyers feel when managing supply risks, product quality checks, and tight budgets. Some look to diversify orders, splitting volumes between Chinese GMP factories — prized for affordability and speed — and Western suppliers, who excel when compliance and documentation matter most. Multi-country sourcing networks build resilience against political or shipping disruptions. A few buyers from Romania, Pakistan, Czechia, and Argentina also experiment with direct negotiations with manufacturers in China, securing not just lower prices but faster production slots. At the same time, buyers in Sweden, Finland, and Denmark push for transparency through stringent audits, supplier qualification trips, and leveraging third-party quality providers to manage supply chain risk. In my dealings, the most successful procurement teams keep three things at the core: tight supplier vetting, clear quality benchmarks, and a willingness to adapt to market shifts coming out of China, India, and the traditional strongholds of the United States, Japan, and the European Union.
